Microeconomics: Cost Structures, Profit Maximization, and Pharmaceutical Pricing

Fundamentals of Cost Structure and Marginal Analysis

  • Marginal Cost (MCMC): Represents the incremental change in total cost resulting from producing one additional unit of output.

  • Total Cost (TCTC) Calculation: Determined across various production levels (Q=0,1,2,etc.Q = 0, 1, 2, \text{etc.}) by combining fixed and variable components.

  • Practice Problem Context: Standard applications include evaluated scenarios such as problem Number 7 and Number 17, which showcase concepts across three distinct problem versions.

Research Assignment Guidelines

  • Assignment Format: An optional research assignment focused on microeconomics topics that allow flexible submission types, including formal written research papers.

  • Objective: Designed to give opportunity for exploring real-world applications and critical policy implications connected to microeconomic principles.

Components of Total Cost: Fixed vs. Variable

  • Fixed Cost (FCFC):

    • Defined as the cost incurred when output quantity is zero (Q=0Q = 0).

    • Remains constant across all levels of production quantity (QQ).

    • Graphically represented as a flat horizontal component that is identical at every output level.

  • Variable Cost (VCVC):

    • Costs that change directly in response to changes in output quantity (QQ).

  • Total Cost Structure:

    • Total Cost=Fixed Cost+Variable Cost\text{Total Cost} = \text{Fixed Cost} + \text{Variable Cost}

Profit Maximization Criteria

  • Profit Evaluation: Calculated for all output and pricing combinations using the relationship:

    • Profit=Total Revenue−Total Cost\text{Profit} = \text{Total Revenue} - \text{Total Cost}

  • Optimal Output and Pricing:

    • Under baseline conditions, profit maximization occurs at an output quantity of Q=23Q = 23 and a price of P=54P = 54

    • Maximization Criterion: The profit-maximizing quantity satisfies the condition where Marginal Revenue equals Marginal Cost (MR=MCMR = MC).

  • Impact of Shifts in Fixed Cost:

    • An increase in fixed costs (e.g., increasing fixed costs to $800\$800) shifts the entire Total Cost curve vertically upward by the amount of the increase.

Irrelevance of Fixed Costs in Pricing and Quantity Decisions

  • Monopoly Price and Production Rule:

    • When fixed costs change, a profit-maximizing monopolist alters nothing regarding its production quantity or product price.

    • Fixed costs are completely irrelevant for determining optimal production quantity and selling price on the supply side because Marginal Cost (MCMC) is determined exclusively by Variable Cost (VCVC).

  • Impact on Overall Profit:

    • Fixed costs affect the magnitude of total profit (Profit\text{Profit} decreases as FCFC increases).

    • Fixed costs do not shift the profit-maximizing intersection where MR=MCMR = MC

  • Illustrative Scenarios:

    • Executive Compensation: If a chief executive officer's (CEO) salary increases from $1,000,000\$1{,}000{,}000 to $5,000,000\$5{,}000{,}000, this raises fixed costs but does not alter the price the firm charges for its product.

    • Overhead and Taxes: Doubling property taxes for a firm (e.g., GlaxoSmithKline or hypothetical monopolies) lowers net profit but leaves the profit-maximizing price and quantity unchanged.

Case Study: Pharmaceutical Pricing of Compavir (Commavir)

  • Research and Development Costs:

    • Prior to market introduction, hundreds of millions of dollars are spent on scientific R&D, development, and regulatory testing.

    • Once approved and brought to market, these development expenses represent sunk fixed costs and are irrelevant to setting ongoing price and quantity.

  • GlaxoSmithKline (GSK) Strategy:

    • GSK priced Compavir (Commavir) at $7,000\$7{,}000 per year / per dose.

    • The active ingredients cost only about $2.50\$2.50 per dose.

    • GSK established the $7,000\$7{,}000 price point by evaluating where MR=MCMR = MC to achieve maximum profit.

    • Cost Drivers:

      • High management expenses (million-dollar executive compensation).

      • Marketing Expenditures: Approximately one-third of every dollar (over $2,000\$2{,}000 out of the $7,000\$7{,}000 price) is spent directly on marketing new drugs.

Market Segmentation, Price Elasticity, and Generic Competition

  • Demand Elasticity Variation:

    • Price-insensitive consumer segments display a steep, nearly vertical demand curve, sustaining high prices.

    • Low-income demographics feature low individual purchasing power, making a $7,000\$7{,}000 price unaffordable for the majority of the population.

  • Cipla Generic Entry Model:

    • Cipla conducts economic profit analysis for lower-income consumer bases and sets a price of approximately $300\$300

    • Total Revenue Curve Structure:

      • Exhibits an inverted U-shape.

      • Because the demand curve is much flatter across a vastly larger volume of customers, Cipla's Total Revenue curve is significantly flattened compared to high-price models.

    • Cost Structure Comparison:

      • Fixed Costs: Cipla operates with significantly lower fixed costs than GSK, as it avoids high management salaries and marketing overhead.

      • Variable Costs: Approximately identical to GSK at roughly $2.50\$2.50 per unit for active ingredients, plus minor additional costs for packaging.

      • Total Cost Curve Mechanics: The slope of Cipla's Total Cost curve (determined by variable costs) matches GSK's, but Cipla's vertical intercept (fixed cost) is substantially lower.

  • Target Operating Points:

    • Profit Maximization: Occurs at output Q1Q_1 where MR=MCMR = MC, generating a price of approximately $300\$300

    • Breakeven Point: Occurs where Total Revenue equals Total Cost (Total Revenue=Total Cost\text{Total Revenue} = \text{Total Cost}), resulting in Profit=0\text{Profit} = 0